Previous exposure to antipsychotic drug treatment is an effective predictor of metabolic disturbances experienced with current antipsychotic drug treatments

Table 3 Comparison of changes in body weight and metabolic parameters over time between the antipsychotic-naïve, low-metabolic risk antipsychotics, and high-metabolic risk antipsychotics groups

Variable	Antipsychotic-naïve group	Low-metabolic risk antipsychotics group	High-metabolic risk antipsychotics group	H	P	ES
Weight (kg)
Week 4	2.84±3.35	2.53±1.86	0.92±2.67	11.87	<0.001	0.358
Week 6	4.24±3.90	3.51±2.16	1.30±3.74	18.07	<0.001	0.352
BMI (kg/m²)
Week 4	0.73±1.76	0.53±0.55	0.10±0.69	6.43	0.002	0.363
Week 6	1.77±2.37	1.30±0.88	0.44±1.33	13.79	<0.001	0.356
Cholesterol (mmol l⁻¹)
Week 4	0.15±1.35	0.35±1.17	0.29±1.21	0.501	0.607	0.369
Week 6	0.45±0.91	0.23±0.83	0.44±0.98	1.28	0.281	0.368
Triglycerides (mmol l⁻¹)
Week 4	0.59±1.08	0.71±0.92	0.51±0.97	0.700	0.498	0.369
Week 6	0.68±0.65	0.61±1.10	0.57±1.20	0.260	0.768	0.369
HDL-C (mmol l⁻¹)
Week 4	-0.11±0.44	0.01±0.44	-0.08±0.62	0.815	0.444	0.368
Week 6	0.00±0.41	-0.01±0.33	-0.04±0.33	0.410	0.663	0.369
LDL-C (mmol l⁻¹)
Week 4	0.57±0.85	0.28±0.83	0.31±0.81	2.39	0.094	0.367
Week 6	0.23±0.67	0.27±0.65	0.80±0.74	18.43	<0.001	0.352
Fasting glucose (mmol l⁻¹)
Week 4	-0.13±1.06	0.01±0.91	-0.01±1.11	0.43	0.65	0.369
Week 6	0.20±0.74	0.14±0.76	-0.03±0.85	2.27	0.106	0.367

HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol

ISSN: 1471-244X